- freely available
Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?
AbstractThe aim of this prospective study was to investigate the diagnostic performance of Borrelia (Bb)-induced interferon (IFN)-γ secretion detected by ELISPOT modified to be feasible for clinical laboratories as a supplementary test to the laboratory diagnosis of Lyme neuroborreliosis (LNB) in an endemic setting. Between 2002 and 2004, patients with symptoms of suspected clinical LNB were included in a study conducted on the Åland islands in the Finnish archipelago, which is a hyper-endemic area for Lyme borreliosis (LB). Fourteen patients with confirmed LNB and 103 patients with non-LNB were included, and the numbers of spontaneous and Bb-induced IFN-γ-secreting cells were assayed by the ELISPOT test. The ELISPOT assay showed a weak diagnostic performance with a sensitivity of 36% and a specificity of 82%. The findings in this study show that this ELISPOT-assay modified to be feasible in clinical routine laboratories is not useful as a supplementary diagnostic tool in the laboratory diagnosis of patients with clinically suspected LNB.
Share & Cite This Article
Nordberg, M.; Forsberg, P.; Nyman, D.; Skogman, B.H.; Nyberg, C.; Ernerudh, J.; Eliasson, I.; Ekerfelt, C. Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? Cells 2012, 1, 153-167.View more citation formats
Nordberg M, Forsberg P, Nyman D, Skogman BH, Nyberg C, Ernerudh J, Eliasson I, Ekerfelt C. Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis? Cells. 2012; 1(2):153-167.Chicago/Turabian Style
Nordberg, Marika; Forsberg, Pia; Nyman, Dag; Skogman, Barbro H.; Nyberg, Clara; Ernerudh, Jan; Eliasson, Ingvar; Ekerfelt, Christina. 2012. "Can ELISPOT Be Applied to A Clinical Setting as A Diagnostic Utility for Neuroborreliosis?" Cells 1, no. 2: 153-167.
Notes: Multiple requests from the same IP address are counted as one view.